Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Chronic Pain Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 18 Oct 16

Research and Markets has announced the addition of the "Chronic Pain - Pipeline Review, H2 2016" report to their offering.

Chronic Pain Chronic pain is an abnormal processing of pain where the original injury or cause of acute pain has resolved, but the warning system has failed to shut off. Chronic pain may originate with an initial trauma/injury or infection, or there may be an ongoing cause of pain. Symptoms include fatigue, sleeplessness, weakened immune system and disability. Medications (pain relievers), nerve blocks, or surgery are some treatments used for chronic pain.

Chronic Pain pipeline therapeutics constitutes close to 132 molecules. Out of which approximately 118 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 16, 15, 1, 56, 19 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 2 molecules, respectively.

Chronic Pain - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Chronic Pain Overview
  3. Therapeutics Development
  4. Pipeline Products for Chronic Pain - Overview
  5. Pipeline Products for Chronic Pain - Comparative Analysis
  6. Chronic Pain - Therapeutics under Development by Companies
  7. Chronic Pain - Therapeutics under Investigation by Universities/Institutes
  8. Chronic Pain Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Chronic Pain - Products under Development by Companies
  13. Chronic Pain - Products under Investigation by Universities/Institutes
  14. Chronic Pain - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Acadia Pharmaceuticals Inc.
  • Astraea Therapeutics, LLC
  • Axsome Therapeutics, Inc.
  • BioDelivery Sciences International, Inc.
  • Biogen Inc
  • Bionomics Limited
  • Camurus AB
  • Cara Therapeutics, Inc.
  • Centrexion Therapeutics Corp
  • Daiichi Sankyo Company, Limited
  • Dompe Farmaceutici S.p.A.
  • Echo Pharmaceuticals B.V.
  • Egalet Corporation
  • Eli Lilly and Company
  • Elite Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Grunenthal GmbH
  • Heron Therapeutics, Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Lohocla Research Corporation
  • Lpath, Inc.
  • MD Biosciences GmbH
  • Merck & Co., Inc.
  • Moberg Pharma AB
  • Pain Therapeutics, Inc.
  • PeriphaGen, Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • Prismic Pharmaceuticals, Inc.
  • Purdue Pharma LP
  • Relmada Therapeutics, Inc.
  • Ribomic Inc.
  • Sea4Us
  • Trevena, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 18/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.